Mode of action and clinical impact of VEGF signaling inhibitors

Expert Review of Anticancer Therapy

Volumn 9, Issue 5, 2009, Pages 649-662

  Soltau, Jens ^a   Drevs, Joachim ^a  

^a SANA KLINIKUM OFFENBACH   (Germany)

Author keywords

Angiogenesis; Bevacizumab; Cediranib; Sorafenib; Sunitinib; Tyrosine kinase inhibitor; Vandetanib; VEGF

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMC 1121B; IRINOTECAN; MONOCLONAL ANTIBODY; MOTESANIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; REGENERON; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; XL 184; ANGIOGENESIS INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGINA PECTORIS; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BLEEDING; BLOOD VESSEL FUNCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GLIOBLASTOMA; HEART INFARCTION; HUMAN; HYPERTENSION; INTESTINE ISCHEMIA; KIDNEY CARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; MONOTHERAPY; NONHUMAN; PANCREAS CANCER; PORTAL VEIN THROMBOSIS; PROGRESSION FREE SURVIVAL; RECTUM CARCINOMA; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SURVIVAL RATE; THROMBOEMBOLISM; THYROID CANCER; TUMOR CELL DESTRUCTION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; DRUG ANTAGONISM; METABOLISM; NEOPLASM;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 68149171591     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.19     Document Type: Review

References (132)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
2. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29, 10-14 (2002).
3. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79, 185-188 (1994).
4. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18 (2002).
5. Ribatti D, Nico B, Crivellato E et al. The history of the angiogenic switch concept. Leukemia 21, 44-52 (2007).
6. Longo R, Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother. Pharmacol. 60, 151-170 (2007).
7. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4-25 (1997).
8. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591 (2008).
9. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, J. Clin. Oncol. 20, 4368-4380 (2002).
10. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011-1027 (2005).
11. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114, 853-865 (2001).
12. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611 (2004).
13. Nilsson M, Heymach JV. Vascular endothelial growth factor (VEGF) pathway. J. Thorac. Oncol. 1, 768-770 (2006).
14. Veeravagu A, Hsu AR, Cai W et al. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Patents Anticancer Drug Discov. 2, 59-71 (2007).
15. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 12, 5018-5022 (2006).
16. Waltenberger J, Claesson-Welsh L, Siegbahn A et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269, 26988-26995 (1994).
17. Ferrara N, Hillan KJ, Gerber HP et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004).
18. Hiratsuka S, Minowa O, Kuno J et al. Flt-1 lacking the tyrosine kinase domain is, sufficient for normal development and angiogenesis in mice. Proc. Natl Acad. Sci. USA 95, 9349-9354 (1998).
19. Paavonen K, Puolakkainen P, Jussila L et al. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol. 156, 1499-1504 (2000).
20. Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439 (1996).
21. Olsson AK, Dimberg A, Kreuger J et al. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mil. Cell Biol. 7, 359-371 (2006).
22. Lee JC, Chow NH, Wang ST et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer. 36, 748-753 (2000).
23. Berns EM, Klijn JG, Look MP et al. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin. Cancer Res. 9, 1253-1258 (2003).
24. George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res. 7, 1932-1936 (2001).
25. Fontanini G, Lucchi M, Vignati S et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J. Natl Cancer Inst. 89, 881-886 (1997).
26. Nagy JA, Vasile E, Feng D et al. Vascular permeability factor/ vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196, 1497-1506 (2002).
27. Barbera-Guillem E, Nyhus JK, Wolford CC et al. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res. 62, 7042-7049 (2002).
28. Asano M, Yukita A, Matsumoto T et al. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res. 55, 5296-5301 (1995).
29. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
30. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003).
31. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 5(Suppl. 1), 3-10 (2000).
32. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997).
33. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
34. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl. J. Med. 357, 2666-2676 (2007).
35. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006).
36. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147 (2004).
37. Wedam SB, Low JA, Yang SX et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24, 769-777 (2006).
38. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
39. Giantonio BJ, Catalano PJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007).
40. Reck M, von Pawel J et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J. Clin. Oncol. 27(8), 1227-1234 (2009).
41. Ton NC, Parker GJM, Jackson A et al. Phase I evaluation of CDP791, a PEGylated di-fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin. Cancer Res. 13, 7113-7118 (2007).
42. Riely GJ, Miller VA. Vascular endothelial growth factor trap in non small cell lung cancer. Clin. Cancer Res. 13(Suppl.), S4623-S4627 (2007).
43. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
44. Wilhelm SM, Adnane L, Newell P et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129-3140 (2008).
45. Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer 92, 1855-1861 (2005).
46. Clark JW, Eder JP, Ryan D et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11, 5472-5480 (2005).
47. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23, 965-972 (2005).
48. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505-2512 (2006).
49. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced dear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
50. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
51. Agarwala SS, Keilholz U, Hogg D et al. Randomized Phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma [abstract]. J. Clin. Oncol. 25 (2007) (Abstract 8510).
52. Goodman VL, Rock EP, Dagher R et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13, 1367-1373 (2007).
53. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003).
54. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24, 25-35 (2006).
55. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
56. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006).
57. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368, 1329-1338 (2006).
58. Chen LL, Sabripour M, Andtbacka RH et al. Imatinib resistance in gastrointestinal stromal tumors. Curr. Oncol. Rep. 7, 293-299 (2005).
59. Demetri GD, van Oosterom AT, Blackstein M et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. J. Clin. Oncol. 23 (16 Suppl.) (2005) (Abstract 400).
60. Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389-4400 (2005).
61. Smith NR, James NH, Oakley I et al. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol. Cancer Ther. 6, 2198-2208 (2007).
62. Padera TP, Kuo AH, Hoshida T et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol. Cancer Ther. 7, 2272-2279 (2008).
63. Tammela T, Zarkada G, Wallgard E et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454, 656-660 (2008).
64. He Y, Kozaki K, Karpanen T et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl Cancer Inst. 94, 819-825 (2002).
65. Su JL, Yang PC, Shih JY et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 9, 209-223 (2006).
66. Heckman CA, Holopainen T, Wirzenius M et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 68, 4754-4762 (2008).
67. Drevs J, Siegert P, Medinger M et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25, 3045-3054 (2007).
68. Batchelor TT, Sprensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
69. Laurie SA, Gauthier I, Arnold A et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol. 26, 1871-1878 (2008).
70. Nikolinakos P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J. Thorac. Oncol. 3(Suppl.), S131-S134 (2008).
71. Cunningham D, Wong RP, D'haens G et al. A Phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): final PFS results. J. Clin. Oncol. 26(Suppl. 12), 4028 (2008).
72. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1), 83-95 (2007).
73. Sridhar SS, Mackenzie MJ, Hotte SJ et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A Phase II trial of the PMH Consortium. J. Clin. Oncol. 26 (20 Suppl.) (2008) (Abstract 5047).
74. Gardner K, Leahy M, Alvarez-Guttierez M, Judson I, Scurr M. Activity of the VEGFR/KIT tyrosine kinase inhibitor cediranib (AZD2171) in alveolar soft part sarcoma. Presented at: Connective Tissue Oncology Society 14th Annual Meeting. London, UK, 13-15 November 2008.
75. Carlomagno F, Vitagliano D, Guida T et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62, 7284-7290 (2002).
76. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62, 4645-4655 (2002).
77. Wu W, Isobe T, Itasaka S et al. ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer. Proc. Am. Assoc. Cancer Res. 45, 1051 (2004).
78. Holden SN, Eckhardt SG, Basser R et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol. 16, 1391-1397 (2005).
79. Natale RB, Bodkin D, Govindan R et al. Vandetanib versus gefitinib in patients with advanced NSCLC: results from a two-part, double-blind, randomized Phase II study. J. Clin. Oncol. (2009).
80. Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled Phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J. Clin. Oncol. 25, 4270-4277 (2007).
81. Heymach JV, Paz-Ares L, de Braud F et al. Randomized Phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 26, 5407-5415 (2008).
82. Haddad RI, Krebs AD, Vasselli J et al. A Phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 26(15 Suppl.), (2008) (Abstract 6024).
83. Heymach J V, Paz-Ares L, De BF et al. Randomized Phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 26(33), 5407-5415 (2008).
84. Wells SA, Gosnell JE, Gagel RF et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label Phase II trial. J. Clin. Oncol. 25(18 Suppl.) (2007) (Abstract 6018).
85. Cohen EE, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a Phase II study. J. Clin. Oncol. 26, 4708-4713 (2008).
86. Hu-Lowe DD, Zou HY, Grazzini ML et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res. 14, 7272-7283 (2008).
87. Wilmes LJ, Pallavicini MG, Fleming LM et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn. Reson. Imaging 25, 319-327 (2007).
88. George DJ. Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clin. Cancer Res. 13, 753S-757S (2007).
89. Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a Phase II study. Lancet Oncol. 8, 975-984 (2007).
90. Bergers G, Song S, Meyer-Morse N et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295 (2003).
91. Spano JP, Chodkiewicz C, Maurel J et al. Efficacy of gemcirabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised Phase II study. Lancet 371, 2101-2108 (2008).
92. Polverino A, Coxon A, Starnes C et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 66, 8715-8721 (2006).
93. Rosen LS, Kurzrock R, Mulay M et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25, 2369-2376 (2007).
94. Sherman SI, Wirth LJ, Droz JP et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N. Engl. J. Med. 359, 31-42 (2008).
95. Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 6, 2012-2021 (2007).
96. Salgia R, Sherman S, Hong D et al. A Phase I study of XL184, a RET, VEGFR2 and MET kinase inhibitor in patients with advanced malignancies, including patients with medullary thyroid cancer. J. Clin. Oncol. 26(15 Suppl.), (2008) (Abstract 3522).
97. Kurzrock R, Sherman S, Hong D et al. A Phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) Eur. J. Cancer 6(Suppl. 12) (2008) (Abstract 379).
98. Kerbel RS, Viloria-Petit A, Klement G et al. 'Accidental' anti-angiogenic drugs, anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur. J. Cancer 36, 1248-1257 (2000).
99. Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother. Pharmacol. 61, 661-668 (2008).
100. Yau T, Chan P, Wong H et al. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology 72(Suppl. 1), 67-71 (2007).
101. Li X, Liu X, Wang J et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res. 23, 2481-2487 (2003).
102. Raig ET, Jones NB, Varker KA et al. VEGF secretion is inhibited by interferon-α in several melanoma cell lines. J. Interferon Cytokine Res. 28, 553-561 (2008).
103. Del VM, Bajetta E, Canova S et al. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13, 4677-4685 (2007).
104. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
105. Bruns CJ, Liu W, Davis DW et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89, 488-499 (2000).
106. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
107. Morgan B, Thomas AL, Drevs J et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J. Clin. Oncol. 21(21), 3955-3964 (2003).
108. Hahn OM, Yang C, Medved M et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J. Clin. Oncol. 26(28), 4572-4578 (2008).
109. Dallas NA, Fan F, Gray MJ et al. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Rev. 26, 433-441 (2007).
110. Bachelder RE, Crago A, Chung J et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 61, 5736-5740 (2001).
111. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987-989 (2001).
112. Browder T, Butterfield CE, Kraling BM et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886 (2000).
113. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
114. Borgstrom P, Bourdon MA, Hillan KJ et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35, 1-10 (1998).
115. Herbst RS, Takeuchi H, Teicher BA. Paditaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother. Pharmacol. 41, 497-504 (1998).
116. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 52, 6702-6704 (1992).
117. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 19, 1195-1206 (2001).
118. Gustafson DL, Merz AL, Zirrolli JA et al. Impact of scheduling on combined ZD6474 and radiotherapy in head and neck tumor xenografts. Eur. J. Cancer Suppl. 2, 45 (2004).
119. Siemann D, Shi W. The VEGFR2 tyrosine kinase inhibitor, ZD6474, enhances the antitumor effect of radiation. Eur. J. Cancer Suppl. 2, 49 (2004).
120. Williams KJ. Telfer BA, Brave S et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin. Cancer Res. 10, 8587-8593 (2004).
121. Kiura K, Nakagawa K, Shinkai T et al. A randomized, double-blind, Phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J. Thorac. Oncol. 3, 386-393 (2008).
122. Kalka C, Masuda H, Takahashi T et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ. Res. 86, 1198-1202 (2000).
123. Bertolini F, Mingrone W, Alietti A et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann. Oncol. 12, 987-990 (2001).
124. Cohen MH, Gootenberg J, Keegan P et al. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12, 713-718 (2007).
125. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22, 2184-2191 (2004).
126. Roodhart JM, Langenberg MH, Witteveen E et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr. Clin. Pharmacol. 3, 132-143 (2008).
127. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 7, 193-201 (2004).
128. Li B, Ogasawara AK, Yang R et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 39, 1095-1100 (2002).
129. Heymach JV, Desai J, Manola J et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin. Cancer Res. 10, 5732-5740 (2004).
130. Motzer RJ, Hoosen S, Bello CL et al. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs 15, 553-561 (2006).
131. Robert C, Faivre S, Raymond E et al. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann. Intern. Med. 143, 313-314 (2005).
132. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 25(5), 740-745 (2009).